Queen’s University Belfast, researchers have developed a take a look at that may be able to detect ovarian cancer in initial stage up to two years earlier than modern approaches.
The researchers found that the presence of four proteins together, referred to as a biomarker panel, shows the possibility of Epithelial Ovarian Cancer (EOC), a sort of ovarian cancer. Practicing these biomarkers, the researchers then developed a screening check that initial studies suggest may be able to detect ovarian cancer as much as two years before current detection exams.
The analysis was carried out in partnership with the University of New South Wales Australia, University of Manchester, University of Milan, and University College London.
The research, revealed in the British Journal of Cancer, concerned the analysis of blood samples from 80 people across seven years.
Dr. Bobby Graham, School of Biological Sciences at Queen’s University and lead writer of the study, explain: “Firstly, we found that the presence of the biomarker panel will allow us to detect EOC. We then developed a screening test to identify this biomarker panel, making this a relatively easy diagnostic test.
“The algorithm designed will display the blood sample and flag any abnormal levels of the proteins associated with cancer. The screening check identifies ovarian cancer as much as two years before the current tests allow.”
Ovarian cancers are epithelial type ovarian cancers, which is cancer that forms in the tissue overlying the ovary. In women in the UK, ovarian cancer is the sixth most common type of cancer. In 2016, 4227 deaths were reported because of EOC.
If diagnosed at stage one of EOC, there’s a 90 % chance of five-year survival compared to 22 % if diagnosed at stage three or four.